845617-99-4

Basic information

• Product Name: 3-Chloro-5-(trifluoroMethyl)pyridazine
• Synonyms: Pyridazine, 3-chloro-5-(trifluoromethyl)-
• CAS NO: 845617-99-4
• Molecular Formula: C5H2ClF3N2
• Molecular Weight: 182.5309896
• Mol File: 845617-99-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 218.2±35.0 °C(Predicted)
• Appearance: /
• Density: 1.504±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.76±0.10(Predicted)
• CAS DataBase Reference: 3-Chloro-5-(trifluoroMethyl)pyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Chloro-5-(trifluoroMethyl)pyridazine(845617-99-4)
• EPA Substance Registry System: 3-Chloro-5-(trifluoroMethyl)pyridazine(845617-99-4)

Safety Data

• Hazardous Substances Data: 845617-99-4(Hazardous Substances Data)

Usage

General Description

3-Chloro-5-(trifluoromethyl)pyridazine is a chemical with the molecular formula C6H2ClF3N2. It is characterized as a clear, colorless to light yellow liquid. 3-Chloro-5-(trifluoroMethyl)pyridazine belongs to the group of organofluorines, which are organic compounds that contain the element fluorine. They are primarily used in the research and development of pharmaceuticals and agrochemicals. The trifluoromethyl group often imparts unique properties to the molecules, such as increased stability and lipophilicity. Like many organofluorines, the exact toxicity and environmental impact of this chemical are not well understood, but care should be taken to handle it responsibly.

Upstream product

• 244268-34-6 5-(trifluoromethyl)pyridazin-3(2H)-one 

Downstream Products

• 1211591-88-6 5-(trifluoromethyl)pyridazine-3-amine 

Relevant articles and documents

KINASE INHIBITORS AND USES THEREOF

Provided are cyclic iminopyridimdine compounds and their bicyclic derivatives, pharmaceutical compositions comprising such compounds, and methods of using such compounds or compositions, such as methods of treating a proliferation disorder, such as a cancer or a tumor, or in some embodiments disease or disorders related to the dysregulation of kinase such as, but not limited to kinases such as MAPK, PDGFR, Src, PAKs, c-Kit, EphA2, EphB4, FGFR, Axl, and c-Met.

COMPOUNDS USEFUL AS CSF1 MODULATORS

This invention relates to novel compounds and to pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as Colony Stimulating Factor 1 Receptor (cFMS) modulators (e.g. cFMS inhibitors). This invention also relates to processes for preparing the compounds, uses of the compounds in treatment and methods of treatment employing the compounds. Specifically, the invention relates to the use of the compounds for the treatment of cancer and autoimmune diseases.